Reading is good for you...
Reading about what's good for you is even better.
August 8, 2022
August 10, 2022
August 2, 2022
Get your Arixtra delivered at your door for FREE
Aspen Pharma Trading
Arixtra (Fondaparinux) belongs to the class of medications called synthetic antithrombotics. It works by blocking clotting factors and enzymes that help the blood to clot.
Medication pricing not available right now.
Please message us or give us a call at 1-855-950-7225.
Arixtra (Fondaparinux) belongs to the class of medications called synthetic antithrombotics. It works by blocking clotting factors and enzymes that help the blood to clot. Circulating Blood Clots are dangerous because they can cause medical problems such as Heart Attack, Stroke, and pulmonary Embolism.
Arixtra (Fondaparinux) is used to treat blood clots in deep veins (deep vein thrombosis [DVT]) and the lungs (pulmonary embolism [PE]). Arixtra (Fondaparinux) can also be used to prevent blood clots for people who have unstable Angina, have had a recent heart attack, or are undergoing certain types of surgery.
Arixtra (Fondaparinux) may be available under multiple brand names and/or in several different forms. Any specific brand name of Arixtra (Fondaparinux) may not be available in all of the forms or approved for all of the conditions discussed here. As well, some forms of Arixtra (Fondaparinux) may not be used for all of the conditions discussed here.
Your doctor may have suggested Arixtra (Fondaparinux) for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking Arixtra (Fondaparinux), speak to your doctor. Do not stop taking Arixtra (Fondaparinux) without consulting your doctor.
Do not give Arixtra (Fondaparinux) to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take Arixtra (Fondaparinux) if their doctor has not prescribed it.
The recommended dose of Arixtra (Fondaparinux) depends on the reason the medication is being used. The dose is injected subcutaneously or SC (under the skin), once daily. Sometimes, in a hospital setting, Arixtra (Fondaparinux) is given intravenously (into the vein).
To prevent clots after surgery, the dose is 2.5 mg injected once daily starting at least 6 hours after surgery.
When treating DVT or PE, the dose depends on body weight and ranges from 5 mg to 10 mg injected SC once daily.
For the management of heart attacks or severe angina, the dose is 2.5 mg SC once daily.
In all cases, it is important to continue using Arixtra (Fondaparinux) until your doctor has determined that the risk of blood clots has passed. This may be because you are mobile again after surgery or because another medication has been introduced to continue the clot prevention.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
If you are injecting Arixtra (Fondaparinux) yourself, your doctor will show you how to use Arixtra (Fondaparinux) properly. If you are not sure how to use it or have questions about how to use it, contact your doctor. Before using Arixtra (Fondaparinux), thoroughly read the patient information provided and ask your doctor if you have any questions. If a caregiver will be giving you the injections, your doctor should instruct them on how to give the injection.
To use Arixtra (Fondaparinux):
It is important to take Arixtra (Fondaparinux) exactly as prescribed by your doctor. If you miss a dose, take it as soon as possible and continue with your regular schedule. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store Arixtra (Fondaparinux) at room temperature and keep out of reach of children.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Arixtra (Fondaparinux). If you are concerned about side effects, discuss the risks and benefits of Arixtra (Fondaparinux) with your doctor.
The following side effects have been reported by at least 1% of people taking Arixtra (Fondaparinux). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Arixtra (Fondaparinux).
2.5 mg/0.5 mL
Each 0.5 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 2.5 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.
5 mg/0.4 mL
Each 0.4 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 5 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.
7.5 mg/0.6 mL
Each 0.6 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 7.5 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.
10 mg/0.8 mL
Each 0.8 mL syringe prefilled with clear and colourless-to-slightly-yellow liquid contains 10 mg of Arixtra (Fondaparinux) sodium. Nonmedicinal ingredients: sodium chloride, water for injection, and sodium hydroxide or hydrochloric acid for pH adjustment.
Do not take Arixtra (Fondaparinux) if you:
There may be an interaction between Arixtra (Fondaparinux) and any of the following:
If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Medications other than those listed above may interact with Arixtra (Fondaparinux). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Arixtra (Fondaparinux).
Bleeding: Arixtra (Fondaparinux) can increase the risk of unwanted or uncontrolled bleeding, particularly if you have a bleeding disorder, ulcers of the digestive system or a recent episode of bleeding after brain, spine, or eye surgery. People who weigh less than 50 kg may also have an increased risk of bleeding. If you believe you may have an increased risk of bleeding problems, discuss with your doctor how Arixtra (Fondaparinux) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Arixtra (Fondaparinux), and whether any special monitoring is needed.
Kidney function: Kidney Disease or reduced kidney function may cause Arixtra (Fondaparinux) to build up in the body, causing side effects. If you have reduced kidney function or kidney disease, discuss with your doctor how Arixtra (Fondaparinux) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Arixtra (Fondaparinux), and whether any special monitoring is needed.
Latex allergy: The needle shield of the pre-filled syringe contains dry natural latex rubber. If you are allergic to latex, this may cause an allergic reaction.
Spinal/epidural hematomas: There have been cases of spinal bleeding and blood clots when antithrombotic medications are used along with spinal or epidural anesthesia. These spinal blood clots may lead to long-term or permanent paralysis. The risk may be greater if people are taking other medications that affect blood clotting (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] such as Naproxen or Ibuprofen, or other anticoagulants), or in people who require repeated epidural or spinal procedures. If you notice a sudden inability to move your body or sudden back pain or tenderness, get medical help immediately.
Pregnancy: Arixtra (Fondaparinux) should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking Arixtra (Fondaparinux), contact your doctor immediately.
Breast-feeding: It is not known if Arixtra (Fondaparinux) passes into breast milk. If you are a breast-feeding mother and are taking Arixtra (Fondaparinux), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Arixtra (Fondaparinux) have not been established for children less than 17 years old.
Seniors: People over the age of 65 years old may be more at risk of bleeding from Arixtra (Fondaparinux).
All material © 1996-2021 MediResource Inc. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition.
August 8, 2022
August 10, 2022
August 2, 2022